Richter's syndrome – update on biology and management

Bibliography

• Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;111:5446-56
   PubMed Web of Science ®Google Scholar
• SEER cancer statistics review (1975–2007) [Internet]. 2013
   Google Scholar
• Tsimberidou AM, O'Brien S, Khouri I, et al. Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. J Clin Oncol 2006;24:2343-51
   PubMed Web of Science ®Google Scholar
• Rossi D, Cerri M, Capello D, et al. Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome. Br J Haematol 2008;142:202-15
   PubMed Web of Science ®Google Scholar
• Maddocks-Christianson K, Slager SL, Zent CS, et al. Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemia. Br J Haematol 2007;139:398-404
   PubMed Web of Science ®Google Scholar
• Rossi D, Spina V, Cerri M, et al. Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome. Clin Cancer Res 2009;15:4415-22
   PubMed Web of Science ®Google Scholar
• Mauro FR, Foa R, Giannarelli D, et al. Clinical characteristics and outcome of young chronic lymphocytic leukemia patients: a single institution study of 204 cases. Blood 1999;94:448-54
   PubMed Web of Science ®Google Scholar
• Robak T, Blonski JZ, Gora-Tybor J, et al. Second malignancies and Richter's syndrome in patients with chronic lymphocytic leukaemia treated with cladribine. Eur J Cancer 2004;40:383-9
   PubMed Web of Science ®Google Scholar
• Thornton PD, Bellas C, Santon A, et al. Richter's transformation of chronic lymphocytic leukemia. The possible role of fludarabine and the Epstein-Barr virus in its pathogenesis. Leuk Res 2005;29:389-95
   PubMed Web of Science ®Google Scholar
• Catovsky D, Richards S, Matutes E, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 2007;370:230-9
   PubMed Web of Science ®Google Scholar
• Parikh SA, Rabe KG, Call TG, et al. Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients. Br J Haematol 2013;162:774-82
   PubMed Web of Science ®Google Scholar
• Solh M, Rai KR, Peterson BL, et al. The impact of initial fludarabine therapy on transformation to Richter's syndrome or prolymphocytic leukemia in patients with chronic lymphocytic leukemia: analysis of an intergroup trial (CALGB 9011). Leuk Lymphoma 2013;54(2):252-4
   PubMed Web of Science ®Google Scholar
• Lortholary P, Boiron M, Ripault P, et al. Leuc'emie lymphouide chronique secondairement associ'ee ‘a une r'eticulopathie maligne, syndrome de richter. fre [Chronic lymphoid leukemia secondarily associated with a malignant reticulopathy: Richter's syndrome]. Nouv Rev Fr Hematol 1964;4:621-44
   PubMedGoogle Scholar
• Tsimberidou AM, O'Brien S, Kantarjian HM, et al. Hodgkin transformation of chronic lymphocytic leukemia: the M. D. Anderson Cancer Center experience. Cancer 2006;107:1294-302
   PubMed Web of Science ®Google Scholar
• Bockorny B, Codreanu I, Dasanu CA. Hodgkin lymphoma as Richter transformation in chronic lymphocytic leukaemia: a retrospective analysis of world literature. Br J Haematol 2012;156:50-66
   PubMed Web of Science ®Google Scholar
• Fraser CR, Wang W, Gomez M, et al. Transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma to interdigitating dendritic cell sarcoma: evidence for transdifferentiation of the lymphoma clone. Am J Clin Pathol 2009;132:928-39
   PubMed Web of Science ®Google Scholar
• Chen W, Jaffe R, Zhang L, et al. Langerhans cell sarcoma arising from chronic lymphocytic lymphoma/small lymphocytic leukemia: lineage analysis and BRAF V600E mutation study. N Am J Med Sci 2013;5:386-91
   PubMedGoogle Scholar
• Jain P, Le X, Young KH, et al. Sequential lymphomas or clonally unrelated richter syndrome of chronic lymphocytic leukemia into mantle cell lymphoma. Clin Lymphoma Myeloma Leuk 2013;13:606-9
   Google Scholar
• Michelis FV, Kourti G, Skertsou M, et al. Richter transformation of chronic lymphocytic leukemia into composite diffuse large B-cell and Hodgkin lymphoma. Leuk Lymphoma 2012;53(11):2302-3
   PubMed Web of Science ®Google Scholar
• Richter MN. Generalized reticular cell sarcoma of lymph Nodes associated with lymphatic leukemia. Am J Pathol 1928;4:285-92. 7
   PubMedGoogle Scholar
• Jain P, Benjamini O, Pei L, et al. Central nervous system Richter's transformation and parvovirus B19 infection. Leuk Lymphoma 2013;54:2070-2
   PubMed Web of Science ®Google Scholar
• Omoti CE, Omoti AE. Richter syndrome: a review of clinical, ocular, neurological and other manifestations. Br J Haematol 2008;142:709-16
   PubMed Web of Science ®Google Scholar
• Bruzzi JF, Macapinlac H, Tsimberidou AM, et al. Detection of Richter's transformation of chronic lymphocytic leukemia by PET/CT. J Nucl Med 2006;47:1267-73
   PubMed Web of Science ®Google Scholar
• Falchi L, Trinh LX, Edith MM, et al. Characteristics and prognosis of patients with aggressive chronic lymphocytic leukemia and Richter's transformation: correlation between FDG/PET, histology and clinical outcomes [abstract]. Blood (ASH Annual Meeting Abstract) 2012;120:927
   Google Scholar
• Papajik T, Myslivecek M, Urbanova R, et al. 2-[18F]fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography examination in patients with chronic lymphocytic leukemia may reveal Richter transformation. Leuk Lymphoma 2014;55(2):314-19
   PubMed Web of Science ®Google Scholar
• Ansell SM, Armitage JO. Positron emission tomographic scans in lymphoma: convention and controversy. Mayo Clin Proc 2012;87:571-80
   PubMed Web of Science ®Google Scholar
• Gine E, Martinez A, Villamor N, et al. Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia ("accelerated" chronic lymphocytic leukemia) with aggressive clinical behavior. Haematologica 2010;95:1526-33
   PubMed Web of Science ®Google Scholar
• Mao Z, Quintanilla-Martinez L, Raffeld M, et al. IgVH mutational status and clonality analysis of Richter's transformation: diffuse large B-cell lymphoma and Hodgkin lymphoma in association with B-cell chronic lymphocytic leukemia (B-CLL) represent 2 different pathways of disease evolution. Am J Surg Pathol 2007;31:1605-14
   PubMed Web of Science ®Google Scholar
• Ma Y, Mansour A, Bekele BN, et al. The clinical significance of large cells in bone marrow in patients with chronic lymphocytic leukemia. Cancer 2004;100:2167-75
   PubMed Web of Science ®Google Scholar
• Abruzzo LV, Rosales CM, Medeiros LJ, et al. Epstein-Barr virus-positive B-cell lymphoproliferative disorders arising in immunodeficient patients previously treated with fludarabine for low-grade B-cell neoplasms. Am J Surg Pathol 2002;26:630-6
   PubMed Web of Science ®Google Scholar
• Ansell SM, Li CY, Lloyd RV, et al. Epstein-Barr virus infection in Richter's transformation. Am J Hematol 1999;60:99-104
   PubMed Web of Science ®Google Scholar
• Melo JV, Catovsky D, Galton DA. The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia. II. Patterns of evolution of 'prolymphocytoid' transformation. Br J Haematol 1986;64:77-86
   PubMed Web of Science ®Google Scholar
• Dungarwalla M, Matutes E, Dearden CE. Prolymphocytic leukaemia of B- and T-cell subtype: a state-of-the-art paper. Eur J Haematol 2008;80:469-76
   PubMed Web of Science ®Google Scholar
• Ok CY, Papathomas TG, Medeiros LJ, et al. EBV-positive diffuse large B-cell lymphoma of the elderly. Blood 2013;122:328-40
   PubMed Web of Science ®Google Scholar
• Asano N, Yamamoto K, Tamaru J, et al. Age-related Epstein-Barr virus (EBV)-associated B-cell lymphoproliferative disorders: comparison with EBV-positive classic Hodgkin lymphoma in elderly patients. Blood 2009;113:2629-36
   PubMed Web of Science ®Google Scholar
• Jain P, Benjamini O, Konoplev S, et al. Spontaneous remission of chemo-immunotherapy related, non-transplant Epstein-Barr virus-associated lymphoproliferative disorder in a patient with chronic lymphocytic leukemia. Leuk Lymphoma 2013;54(11):2540-2
   PubMed Web of Science ®Google Scholar
• Roschewski M, Wilson WH. EBV-associated lymphomas in adults. Best Pract Res Clin Haematol 2012;25:75-89
   PubMed Web of Science ®Google Scholar
• Louissaint A Jr, Ferry JA, Soupir CP, et al. Infectious mononucleosis mimicking lymphoma: distinguishing morphological and immunophenotypic features. Mod Pathol 2012;25(8):1149-59
   PubMed Web of Science ®Google Scholar
• Fabbri G, Khiabanian H, Holmes AB, et al. Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome. J Exp Med 2013;210(11):2273-88
   PubMed Web of Science ®Google Scholar
• Chigrinova E, Rinaldi A, Kwee I, et al. Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome. Blood 2013;122(15):2673-82
   PubMed Web of Science ®Google Scholar
• Rossi D, Spina V, Deambrogi C, et al. The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. Blood 2011;117:3391-401
   PubMed Web of Science ®Google Scholar
• Rinaldi A, Mensah AA, Kwee I, et al. Promoter methylation patterns in Richter syndrome affect stem-cell maintenance and cell cycle regulation and differ from de novo diffuse large B-cell lymphoma. Br J Haematol 2013;163(2):194-204
   PubMed Web of Science ®Google Scholar
• Jain P, Young KH. Haematological cancer: Richter's transformation in CLL-a distinct lymphoma. Nat Rev Clin Oncol 2014;11(1):6-8
   Google Scholar
• Timar B, Fulop Z, Csernus B, et al. Relationship between the mutational status of VH genes and pathogenesis of diffuse large B-cell lymphoma in Richter's syndrome. Leukemia 2004;18:326-30
   PubMed Web of Science ®Google Scholar
• Rossi D, Rasi S, Spina V, et al. Different impact of NOTCH1 and SF3B1 mutations on the risk of chronic lymphocytic leukemia transformation to Richter syndrome. Br J Haematol 2012;158:426-9
   PubMed Web of Science ®Google Scholar
• Cobo F, Martinez A, Pinyol M, et al. Multiple cell cycle regulator alterations in Richter's transformation of chronic lymphocytic leukemia. Leukemia 2002;16:1028-34
   PubMed Web of Science ®Google Scholar
• Tsimberidou AM, Keating MJ, Bueso-Ramos CE, et al. Epstein-Barr virus in patients with chronic lymphocytic leukemia: a pilot study. Leuk Lymphoma 2006;47:827-36
   PubMed Web of Science ®Google Scholar
• de Leval L, Vivario M, De Prijck B, et al. Distinct clonal origin in two cases of Hodgkin's lymphoma variant of Richter's syndrome associated With EBV infection. Am J Surg Pathol 2004;28:679-86
   PubMed Web of Science ®Google Scholar
• Tzankov A, Fong D. Hodgkin's disease variant of Richter's syndrome clonally related to chronic lymphocytic leukemia arises in ZAP-70 negative mutated CLL. Med Hypotheses 2006;66(3):577-9
   Google Scholar
• Reiniger L, Bodor C, Bognar A, et al. Richter's and prolymphocytic transformation of chronic lymphocytic leukemia are associated with high mRNA expression of activation-induced cytidine deaminase and aberrant somatic hypermutation. Leukemia 2006;20:1089-95
   PubMed Web of Science ®Google Scholar
• Rinaldi A, Mian M, Kwee I, et al. Genome-wide DNA profiling better defines the prognosis of chronic lymphocytic leukaemia. Br J Haematol 2011;154:590-9
   PubMed Web of Science ®Google Scholar
• De Paoli L, Cerri M, Monti S, et al. MGA, a suppressor of MYC, is recurrently inactivated in high risk chronic lymphocytic leukemia. Leuk Lymphoma 2013;54:1087-90
   PubMed Web of Science ®Google Scholar
• Rossi D, Gaidano G. Richter syndrome: molecular insights and clinical perspectives. Hematol Oncol 2009;27:1-10
   PubMed Web of Science ®Google Scholar
• Aydin S, Rossi D, Bergui L, et al. CD38 gene polymorphism and chronic lymphocytic leukemia: a role in transformation to Richter syndrome? Blood 2008;111:5646-53
   PubMed Web of Science ®Google Scholar
• Rasi S, Spina V, Bruscaggin A, et al. A variant of the LRP4 gene affects the risk of chronic lymphocytic leukaemia transformation to Richter syndrome. Br J Haematol 2011;152:284-94
   PubMed Web of Science ®Google Scholar
• Tsimberidou AM, O'Brien SM, Cortes JE, et al. Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disorders. Leuk Lymphoma 2002;43:767-72
   PubMed Web of Science ®Google Scholar
• Dabaja BS, O'Brien SM, Kantarjian HM, et al. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin (daunoXome), and dexamethasone (hyperCVXD) regimen in Richter's syndrome. Leuk Lymphoma 2001;42:329-37
   PubMed Web of Science ®Google Scholar
• Tsimberidou AM, Kantarjian HM, Cortes J, et al. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia. Cancer 2003;97:1711-20
   PubMed Web of Science ®Google Scholar
• Tsimberidou AM, Murray JL, O'Brien S, et al. Yttrium-90 ibritumomab tiuxetan radioimmunotherapy in Richter syndrome. Cancer 2004;100(10):2195-200
   Web of Science ®Google Scholar
• Velasquez WS, Cabanillas F, Salvador P, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 1988;71:117-22
   PubMed Web of Science ®Google Scholar
• Velasquez WS, McLaughlin P, Tucker S, et al. ESHAP – an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol 1994;12:1169-76
   PubMed Web of Science ®Google Scholar
• Wang YF, Curtis JE, Lipton J, et al. Cytosine arabinoside (ara-C) and cis-dichlorodiammineplatinum II (cisplatin) alone and in combination: effects on acute myeloblastic leukemia blast cells in culture and in vivo. Leukemia 1991;5:522-7
   PubMed Web of Science ®Google Scholar
• Li L, Liu X, Glassman AB, et al. Fludarabine triphosphate inhibits nucleotide excision repair of cisplatin-induced DNA adducts in vitro. Cancer Res 1997;57:1487-94
   PubMed Web of Science ®Google Scholar
• Yang LY, Li L, Keating MJ, Plunkett W. Arabinosyl-2-fluoroadenine augments cisplatin cytotoxicity and inhibits cisplatin-DNA cross-link repair. Mol Pharmacol 1995;47:1072-9
   PubMed Web of Science ®Google Scholar
• Gandhi V, Nowak B, Keating MJ, et al. Modulation of arabinosylcytosine metabolism by arabinosyl-2-fluoroadenine in lymphocytes from patients with chronic lymphocytic leukemia: implications for combination therapy. Blood 1989;74:2070-5
   PubMed Web of Science ®Google Scholar
• Mathe G, Kidani Y, Segiguchi M, et al. Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum. Biomed Pharmacother 1989;43:237-50
   PubMed Web of Science ®Google Scholar
• Tsimberidou AM, Wierda WG, Plunkett W, et al. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2008;26:196-203
   PubMed Web of Science ®Google Scholar
• Tsimberidou AM, Wierda WG, Wen S, et al. Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed/refractory chronic lymphocytic leukemia or Richter syndrome. Clin Lymphoma Myeloma Leuk 2013;13:568-74
   PubMed Web of Science ®Google Scholar
• Jenke P, Eichhorst B, Busch R, et al. Cyclophosphamide, adriamycin, vincristine and prednisone plus rituximab (CHOP-R) in fludarabine (F) refractory chronic lymphocytic leukemia (CLL) or CLL with autoimmune cytopenia (AIC) or Richter's transformation (RT): final analysis of a phase II study of the German CLL study group. ASH Annual Meeting Abstracts 2011;118(21):2860
   Google Scholar
• Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013;369:32-42
   PubMed Web of Science ®Google Scholar
• Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2013;31:88-94
   PubMed Web of Science ®Google Scholar
• Cwynarski K, van Biezen A, de Wreede L, et al. Autologous and allogeneic stem-cell transplantation for transformed chronic lymphocytic leukemia (Richter's syndrome): a retrospective analysis from the chronic lymphocytic leukemia subcommittee of the chronic leukemia working party and lymphoma working party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2012;30:2211-17
   PubMed Web of Science ®Google Scholar